Cancer Care Ontario | Cancer Care Ontario

venetoclax - Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

venetoclax

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

May 2024

Regimen

CISPPEME

Cancer Type:

Gastrointestinal,

Mesothelioma (Peritoneal)

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Drugs Used:

pemetrexed,

CISplatin

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Jan 2024

Drug

alpelisib

Other Name(s): Piqray®

Quick Link(s): Drug Monograph, Patient Info Sheet

Jun 2024

Regimen

NIVL(MNT)

Cancer Type:

Skin,

Melanoma

Show More Show more tags

, Show Less Show fewer tags

Intent: Adjuvant

Drugs Used:

nivolumab (Unfunded)

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

BLIN

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Show More Show more tags

, Show Less Show fewer tags

Intent: Curative

Funding:

New Drug Funding Program

Blinatumomab - Minimal Residual Disease (MRD)-Positive B-cell Precursor Acute Lymphoblastic Leukemia

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

blinatumomab

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Oct 2024

Guidelines and Advice

Hereditary Cancer Testing Eligibility Criteria: Version 3.1

Status: Current
Version: 3.1

Oct 2024

Regimen

LARO

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

larotrectinib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2024

Regimen